linjc16/ctgov huggingface dataset:
Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the effect of this CR program on the improvement of myocardial function using the three-dimensional speckle tracking echocardiography (3D-STE) in AMI patients.

Detailed Description
-----------------
The effect of early short-term home-based cardiac rehabilitation (CR) program on left ventricular function in acute myocardial infarction (AMI) patients is not clear yet.

Official Title
-----------------
Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Behavioral: entailing an early home-based CR program
* Other: enter the usual care program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being aged 18-65 years with a confirmed AMI diagnosis Being suitable for the CR program Undergoing PCI at the entry Exclusion Criteria: Known ischemic heart disease, heart valvular lesions, intra-ventricular conduction disturbances, malignant arrhythmia, cardiac shock, and poor echocardiographic conditions to take STE examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: the rehabilitation group<br>entailing an early home-based CR program | Behavioral: entailing an early home-based CR program<br>* enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)<br>|
| Other: the control group<br>enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care. | Other: enter the usual care program<br>* enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| myocardial function using the three-dimensional speckle tracking echocardiography (3D-STE) |  | Change from baseline strain parameters at four-week follow-up |
Gender Dysphoria and Transition

Study Overview
=================
Brief Summary
-----------------
Persons with gender dysphoria present the difficulties of access to health care. Little time is devoted to education of health professionals about the care of transgender persons. According to the proposal of the French Ministry of Social Affairs and Health there is a need to increase knowledge in this area and to improve the care of transgender people including prevention and screening. Similarly, little is known about social and medical needs of the transgender population. This project proposes to illustrate gender dysphoria through testimonies of transgender people with the aim to increase the investigator's understanding aout the needs and the desires of this population and to describe the process of medical and social transition.

Official Title
-----------------
Gender Dysphoria and Transition: Testimony From Transgender People

Conditions
-----------------
Gender Dysphoria

Intervention / Treatment
-----------------
* Other: collection of testimonies from transgender people


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Person affiliated to a social security system Person having received complete information on the organisation of the research and having signed the informed consent Person having carried out a prior clinical examination adapted to the research Age> 18 years Diagnosis of gender incongruence (dysphoria) according to the international classification of diseases, revision 11 Exclusion Criteria: Severe, uncontrolled psychiatric or somatic illness Substance and alcohol addiction Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: collection of testimonies from transgender people|guided interview|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Illustrate the real-life experiences of transgender people |  | 4 months |
Pain and Readmission After Lap IPOM vs. Robotic Ventral Hernia Repair

Study Overview
=================
Brief Summary
-----------------
Comparison of results after rTARUP and lap IPOM in patients with small- and medium-sized ventral hernia. Retrospective cohort study of consecutive patients undergoing rTARUP or IPOM repair for small or medium-sized primary ventral and incisional hernias. The primary outcome was the postoperative need for transverse abdominis plane (TAP) block or epidural catheter, secondary outcomes were 30-day complications, and length of stay. All patients underwent elective surgery and were followed for 30 days postoperatively.

Detailed Description
-----------------
Single-center retrospective cohort study of consecutive patients undergoing rTARUP or IPOM repair for small or medium-sized primary ventral and incisional hernias. The primary outcome was the postoperative need for transverse abdominis plane (TAP) block or epidural catheter, secondary outcomes were 30-day complications, and length of stay. All patients underwent elective surgery and were followed for 30 days postoperatively.

Official Title
-----------------
Less Postoperative Pain and Length of Stay After Robotic-assisted Laparoscopic Transabdominal Repair With Retro Rectus Mesh Placement (rTARUP) Compared With Laparoscopic Intraperitoneal Onlay Mesh Repair (IPOM) for Small and Medium-sized Ventral Hernias

Conditions
-----------------
Hernia, Ventral

Intervention / Treatment
-----------------
* Procedure: robotic repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients undergoing elective minimally invasive repair for small or medium-sized primary ventral or incisional hernia repairs at one academic hernia center with an unrestricted patient referral. Consecutive patients undergoing IPOM (December 1st, 2017 - December 1st, 2018) and rTARUPrRetrorectus (March 1st, 2021 - June 1st, 2021). Exclusion Criteria: open repairs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IPOM<br>receiving laparoscopic intraperitoneal onlay mesh repair | Procedure: robotic repair<br>* robotic assisted retromuscular hernia repair<br>|
| rTARUP<br>recieving robotic assited retromuscular repair | Procedure: robotic repair<br>* robotic assisted retromuscular hernia repair<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| epidural blockade or TAP block | postoperative pain requiring epidural or TAP block | 0-1 postoperative day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| readmissison | if the patients get readmitted during the follow-up | 30 days | 
| complications | if the patients get any medical or surgical complication during the follow-up | 30 days |
Radio/Pathological Evaluation of Tongue Cancer Infiltration

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the good correlation and prediction of the DOI for the post-operative pathological results and prognosis.

Official Title
-----------------
An Evaluation of the Radio/Pathological Correlation of Depth Of Invasion for Oral Squamous Cell Carcinoma, a Retrospective Study in a University Hospital in Lyon

Conditions
-----------------
Oral Squamous, Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Radiologic and pathological review.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients chirurgically treated for an OSCC T1 T2 T3 CT scanner in their medical file Exclusion Criteria: T4 R+ résection Artefacts on CT scanner
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients who improved surgical treatment for oral cavity cancer<br>T1 T2 and T3 OSCC tumor, patients who have a recent evaluation cervico thoracic scanner in their medical files. | Other: Radiologic and pathological review.<br>* We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses. The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon). Then we will analyse the correlation between the radiological and the pathological analysis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome will be the measure of the correlation of the depth of invasion on the radiological pre operative images and of the pathological analyses on the resection piece. | With a Bland Altman analysis we will assess the good correlation between the pre and post operatory mesures of the depth of invasion in the oral squamous cell carcioma | The outcome will be measured at the inclusion of the patient in the current study. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DOI, Infiltration, Oral cavity cancer, OSCC, Tongue cancer, CT scanner
A Study of LY2409021 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Official Title
-----------------
A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects

Conditions
-----------------
Healthy Participants

Intervention / Treatment
-----------------
* Drug: LY2409021


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males or females as determined by medical history Satisfactory clinical laboratory and physical examination tests Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m^2) Exclusion Criteria: - Abnormal electrocardiograms (ECGs)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY2409021<br>Single oral dose of 20 milligrams (mg) LY2409021. | Drug: LY2409021<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021 | Area under the concentration versus time curve from zero to infinity (AUC[0-inf]) of LY2409021 is presented. | Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose | 
| Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021 |  | Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose | 
| Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) of LY2409021 |  | Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose |
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.

Official Title
-----------------
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation

Conditions
-----------------
Hematologic Malignancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients : 18 years of age and older with hematological malignancies and subject to allogeneic HSCT with health insurance coverage (bénéficiaire ou ayant droit) having signed a written informed consent. Inclusion criteria of donor 18 years of age and older with health insurance coverage (bénéficiaire ou ayant droit) having signed a specific written informed consent. Exclusion criteria of recipient and donor Absence of written informed consent Patient or donor on AME Patient or donor on AME or under protection by law, tutorship or curatorship Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| B cells reconstitution | B cell clusters as assess by CyTOF technology | at day 100 days post-transplant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| B cells reconstitution | B cell clusters as assess by CyTOF technology | at 6 months post-transplant | 
| Perturbations in growth or differentiation of progenitor/precursor of B cells | Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology | at 100 days post transplant | 
| Perturbations in growth or differentiation of progenitor/precursor of B cells | Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology | at 6 months post-transplant |
Retroclavicular Approach to Infraclavicular Block

Study Overview
=================
Brief Summary
-----------------
In this study, the primary objective was to estimate the minimum effective volume of bupivacaine 0.5% resulting in successful block in 50% of patients (MEV50) for ultrasound-guided retroclavicular approach to infraclavicular brachial plexus block.

Detailed Description
-----------------
Two rules were used to stop the study. First stopping rule was a fixed-sample-size. The investigators used an up-and-down method to estimate the threshold for an all-or-none response for present study design. Therefore, for sample size calculation, the investigators applied the formula by Dixon and Massey, n=2(SD/SEM)2 (SD: standard deviation and SEM: standard error of mean). Second stopping rule included demonstration of minimum of five consecutive up-and-down sequences. On the basis of previous studies with similar binary outcomes, the investigators estimated that a priori a minimum of five negative-positive up-and down deflections was required to calculate MEV50.

Official Title
-----------------
Minimum Effective Volume of Bupivacaine 0.5% for Ultrasound-guided Retroclavicular Approach to Infraclavicular Brachial Plexus Block

Conditions
-----------------
Bupivacaine

Intervention / Treatment
-----------------
* Other: minimum effective volume


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who received infraclavicular brachial plexus block for elective elbow, forearm, wrist, or hand surgery American Society of Anesthesiologists class I, II or III Exclusion Criteria: patients <18 years old >65 years old body mass index (BMI) <20 or >35 kg/m2 inability to provide written informed consent refusal of regional anesthesia pregnancy contraindication for regional anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The minimum effective volume of bupivacaine 0.5% resulting in successful block in 50% of patients (MEV50) | The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| estimate the minimum effective volume in 95% of patients (MEV95). | To calculate the MEV95, data were analyzed using probit transformation and logistic regression. | 30 minutes |
Tigecycline In-Vitro Surveillance Study In Taiwan

Study Overview
=================
Brief Summary
-----------------
In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.

Official Title
-----------------
Tigecycline In-Vitro Surveillance Study In Taiwan

Conditions
-----------------
Community Acquired Infections

Intervention / Treatment
-----------------
* Other: In-vitro testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically relevant causative isolate (no duplicates) - The isolate must meet the laboratory criteria of significant pathogen and be considered the probable causative agent of a hospital or community acquired infection. Sources - All body sites are acceptable clinical sources for isolates to be included in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures. Within study group - Only isolates defined by the protocol are to be included. Exclusion Criteria: Limited isolates from sources - No more than 10 % of all isolates from this study will be derived from urine cultures. No banked or stored isolates. No duplicate isolates - Only one isolate per patient is permitted. Outside study group - Any isolate other than those defined by protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | Other: In-vitro testing<br>* This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prior to 2009: Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90by pathogen, tested by E-test. |  | in vitro study therefore not applicable | 
| Post-2009: Susceptibility data of MIC, MIC50, MIC90 by pathogen, tested by micro-dilution method |  | in vitro study therefore not applicable | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prior to 2009: 1. Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90 by pathogen, tested by micro-dilution method 2. Susceptibility data of inhibition zone diameter(mm) by pathogen, tested by paper disc. |  | in vitro study therefore not applicable | 
| Post-2009: Susceptibility data of inhibition zone diameter (mm) by pathogen, tested by paper disc. |  | in vitro study therefore not applicable | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microdilution method, Tygacil, Tigecycline, In-Vitro